The changes in daily urinary excretion of follicle-stimulating and luteinizing hormones caused by ethinyl-estradiol and conjugated equine estrogens in low doses have been studied with urine samples collected from eight normal menstruat ing women, three normal men, and seven women with abnormal menstrual cycle.
Case 2. K.T., a 22-year-old unmarriedwoman had a chief complaint of primary amenorrhea. She was 143.2 cm in height and 44.5 kg in weight. She had poorly developed secondary sexual characteristics, and shallow vagina and uterus were palpable on pelvic examination. The ovaries could not be touched in this way, but their presence could not be excluded inasmuch as this patient once ovulated in response to gonadotropin (PMS+HGC) administered by the one-two cyclic method. No remarkable congenital deformities were discovered on physical examination and the patient was found to be chromatin-positive. Thyroid function was normal, BMR being +12% and 24 hours' 131I-uptake being 28%, and the thyroidal scintigram revealing a normal size and position of the gland. The ACTH stimulation test and the Methopyrapone test were within normal limits. Urinary steroid determinations gave the following results: 32.5,ug total estrogens (estrone 7.8,ug, estradiol 9.1,ug, and 15.6,ug of estriol per 24 hours), 0.78 mg pregnanediol per 24 hours, 2.1 mg 17-ketosteroids per 24 hours, and 2.1 mg 17 OHCS per 24 hours.
As shown in Fig. 2 , she did not show a reaction to a daily dose of 0.05 mg of EE for urinary FSH excretion, nor did she react to a daily dose of 0.625 mg of Premarin for LH excretion determination. There are no changes in the FSH and LH excretion with estrogens used.
Other readings are the same as in Fig. L During the second day of EE in the FSH test, the patient developed adrenal crisis and was treated with hydrocortisone injections and supportive therapy, but the FSH test with EE was not stopped. Cortisone tablets in. a daily dose of 25 mg were given adjunctively and maintained during the entire estrogen trial. No important changes in the basal values were observed for urinary FSH excretion during EE administration or for urinary LH excretion during Premarin test, No effect on gonadotropin excretion was exerted by additional cortisone therapy. No further adrenal crisis occurred. The results of FSH-LH test on this patient are presented in Fig. 4 
RESULTS
Changes in daily urinary RASH excretion in normal women. The daily changes of urinary FSH excretion under the action of ethinyl-estradiol (EE) in a daily dose of 0.05 mg were studied in eight normal menstruating women. The subjects were given a daily dose of EE for four consecutive days starting early in their menstrual cycles and the daily changes in urinary FSH excretion were measured and graphed in the composite curve in Fig. 5 . It was observed that on the second day of EE and from the fourth day, the curve tended to rise and the elevation Comparison of the daily changes of the mean urinary ESH excretion between normal menstruating women and amenorrheal women. Table 1 shows the comparison between eight normal menstruating women and six amenorrheal women. From this table it was possible to conclude that the basal values of normal and abnormal women were not different (p>0.05), and that, from the second day of EE on, statistically significant differences appeared especially on the second (p<0.05) and fourth days (p<0.001). The results on the fifth and the sixth days were not compared, because only 3 cases of women with menstrual disorders were examined and the limited number made a comparative study of little value. It should be noted that the Premarin test in our normal volunteers was performed during the late proliferative phase of the menstrual cycle, because the FSH response to ethinyl-estradiol could be elicited only after 8 days from the early days of menses. Also, as it is possible to observe in Table 2 , Premarin in low doses had some effect on the length of menstrual cycles. Only one of the eight normal women showed no changes in the length of her menstrual cycle, whereas in the other seven the menstrual cycles as determined prior to the experiment were prolonged by two to twelve days, the mean prolongation being 5.8 days.
In order to ascertain whether the Premarin-induced response of urinary LH excretion was influenced by the plan of medication or the order of ethinyl-estradiol in Fig. 11 . In this study ethinyl-estradiol was given first and Premarin later in the same way as in cases of normal and amenorrheal women. In normal men, there also appeared an LH peak on the fourth (two cases) or on the fifth (one case) day of Premarin administration. Because of the small number of cases , statistical treatment was not applied.
Comparison of the effects of Premarin in a daily dose of 0.625 mg on urinary LH excretion between normal women and non-menstruating women . Table 3 shows the results from eight normal menstruating women at the early and late proliferative phase of the menstrual cycle, and four cases of women with abnormal menstrual We noticed that LH excretion response to the action of Premarin was different between normal women and normal men, as was also mentioned previously in the case of FSH excretion upon stimulation by ethinyl-estradiol. The paper of Harris," who proved a different pattern between the two sexes at the hypothalamic level, may also support our observation. Therefore, it seems reasonable to conclude that the abnormal non-menstruating woman tends to have a `male type' (acyclic) in both LH response and FSH excretion as regards the feedback control mechanism of gonadotropin secretion.
Briefly we can state that 0.05 mg of ethinyl-estradiol exerts a stimulatory effect on FSH excretion in the normal woman during the second and fourth to fifth days, and that this response is statistically different front that of the normal man and the woman with menstrual disorders. We cannot yet state that different doses or different times of administration of the drug may have different actions, and further studies are necessary about this question.
We can also state that Premarin exerts its action principally on women with abnormal menstrual cycle and probably in the normal man by increasing LH excretion on the third to fifth days of its administration. We are not certain whether different doses, times or routes of Premarin administration might produce a different response. The problem of the action of Premarin on LH secretion awaits also further studies.
Our FSH-LH test with ethinyl-estradiol and Premarin in low doses seems to contribute to the solution of some clinical problems related to women with abnormal menstrual cycle and especially to those related to abnormalities of gonadotropin secretion mechanisms.
